Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX TWISTHALER versus ZYLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX TWISTHALER versus ZYLET.
ASMANEX TWISTHALER vs ZYLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid that binds to the glucocorticoid receptor, leading to inhibition of inflammatory mediators (e.g., cytokines, chemokines, adhesion molecules) and suppression of inflammatory cell migration and activation in the airways.
Loteprednol etabonate is a corticosteroid that inhibits phospholipase A2 activity, reducing prostaglandin and leukotriene synthesis. Tobramycin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
Inhalation: 1-2 inhalations twice daily (morning and evening). Typical adult dose: 200-400 mcg twice daily. Maximum: 800 mcg/day.
One to two drops into the conjunctival sac of the affected eye(s) every 4 to 6 hours. In severe cases, every 1 to 2 hours for the first 24 to 48 hours.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation via ASMANEX TWISTHALER is approximately 5 hours (range 4–6 hours) in patients with asthma. This relatively short half-life supports twice-daily or once-daily dosing with sustained clinical effect due to prolonged local retention in the lungs.
ZYLET: not applicable (fixed-dose combination); Loteprednol: 2-3 hours; Tobramycin: 2-3 hours. Clinical context: no accumulation with qid dosing.
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver via CYP3A4. Unchanged drug and metabolites are excreted primarily in the feces via biliary elimination (approximately 74% of a single oral dose) and to a minor extent in the urine (approximately 8%). For inhaled doses, renal excretion of unchanged drug is negligible (<1% of administered dose).
Renal (30% unchanged), biliary/fecal (70% as metabolites)
Category C
Category C
Corticosteroid, Inhaled
Corticosteroid/Antibiotic Combination (Ophthalmic)